We have located links that may give you full text access.
Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease.
European Journal of Nuclear Medicine and Molecular Imaging 2019 Februrary
PURPOSE: The spatial resolution of 18 F-fluorodeoxyglucose PET does not allow the specific cellular origin of its signal to be determined, but it is commonly accepted that transport and trapping of 18 F-fluorodeoxyglucose reflects neuronal glucose metabolism. The main frameworks for the diagnosis of Alzheimer's disease suggest that hypometabolism measured with 18 F-fluorodeoxyglucose PET is a biomarker of neuronal injury and neurodegeneration. There is preclinical evidence to suggest that astrocytes contribute, at least partially, to the in vivo 18 F-fluorodeoxyglucose PET signal. However, due to a paucity of PET tracers for imaging astrocytic processes, the relationship between astrocyte function and glucose metabolism in human brain is not fully understood. The aim of this study was to investigate the longitudinal association between astrocyte function and glucose metabolism in Alzheimer's disease.
METHODS: The current investigation combined longitudinal PET data from patients with autosomal dominant Alzheimer's disease, including data on astrocyte function (11 C-deuterium-L-deprenyl binding) and glucose metabolism (18 F-fluorodeoxyglucose uptake). Research participants included 7 presymptomatic and 4 symptomatic mutation carriers (age 44.9 ± 9.8 years and 58.0 ± 3.7 years, respectively) and 16 noncarriers (age 51.1 ± 14.2 years). Eight carriers and eight noncarriers underwent longitudinal follow-up PET imaging at an average of 2.8 ± 0.2 and 3.0 ± 0.5 years from baseline, respectively.
RESULTS: Longitudinal decline in astrocyte function as measured using 11 C-deuterium-L-deprenyl PET was significantly associated with progressive hypometabolism (18 F-fluorodeoxyglucose uptake) in mutation carriers; no significant association was observed in noncarriers.
CONCLUSION: The emerging data shift the accepted wisdom that decreases in cerebral metabolism measured with 18 F-fluorodeoxyglucose solely reflect neuronal injury, and places astrocytes more centrally in the development of Alzheimer's disease.
METHODS: The current investigation combined longitudinal PET data from patients with autosomal dominant Alzheimer's disease, including data on astrocyte function (11 C-deuterium-L-deprenyl binding) and glucose metabolism (18 F-fluorodeoxyglucose uptake). Research participants included 7 presymptomatic and 4 symptomatic mutation carriers (age 44.9 ± 9.8 years and 58.0 ± 3.7 years, respectively) and 16 noncarriers (age 51.1 ± 14.2 years). Eight carriers and eight noncarriers underwent longitudinal follow-up PET imaging at an average of 2.8 ± 0.2 and 3.0 ± 0.5 years from baseline, respectively.
RESULTS: Longitudinal decline in astrocyte function as measured using 11 C-deuterium-L-deprenyl PET was significantly associated with progressive hypometabolism (18 F-fluorodeoxyglucose uptake) in mutation carriers; no significant association was observed in noncarriers.
CONCLUSION: The emerging data shift the accepted wisdom that decreases in cerebral metabolism measured with 18 F-fluorodeoxyglucose solely reflect neuronal injury, and places astrocytes more centrally in the development of Alzheimer's disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app